Applied Nutrition posts record profit as whey prices soar

Applied Nutrition said a five‑fold jump in whey protein prices will erode its margins next year, even as it announced a 40% rise in adjusted pre‑tax profit for the year to August.

Profit surge amid rising costs

The Merseyside‑based firm, founded in 2014 by Tom Ryder, said adjusted pre‑tax profit climbed to £49m, a 13% increase on the forecast and well above market expectations. Revenue is set to exceed £200m for the first time, and shares jumped 7.5% at the open.

Our adjusted pre‑tax profit rose by more than 40 per cent.

Weight‑loss drugs reshape protein market

Whey prices have quintupled in recent years, driven largely by demand from users of GLP‑1 drugs such as Wegovy and Mounjaro. A side‑effect of these medications is muscle atrophy, prompting patients to increase protein intake and add weight‑training to preserve lean mass. This shift has pushed up demand for whey, the most common protein in shakes, bars and supplements, at a time when supply chains are relatively fixed.

Outlook and wider ripple effects

Applied Nutrition expects the price pressure to continue, meaning the company may need to pass costs onto consumers or seek alternative protein sources. The trend mirrors broader industry moves: food giants like Nestle and Pepsico are expanding nutrient‑rich ready meals for people with suppressed appetites, while investors such as Terry Smith of Fundsmith have warned that GLP‑1 drugs could curb alcohol demand, prompting a stake sale in Diageo.

Analysts see the whey surge as a signal that the rapid rollout of weight‑loss drugs will keep reshaping related markets. If prices remain high, firms reliant on whey may see tighter margins, while consumers could face higher costs for protein‑based products.